Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 37 entries
Sorted by: Best Match Show Resources per page
Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention.

PharmacoEconomics - open

Oyagüez I, Suárez C, López-Sendón JL, González-Juanatey JR, de Andrés-Nogales F, Suárez J, Polanco C, Soto J.
PMID: 31673882
Pharmacoecon Open. 2020 Sep;4(3):485-497. doi: 10.1007/s41669-019-00186-7.

OBJECTIVE: Our objective was to assess the cost effectiveness of apixaban versus edoxaban in the prevention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) in Spain.METHODS: We customized a Markov model with ten health states...

Cite
Oyagüez I, Suárez C, López-Sendón JL, et al. Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention. Pharmacoecon Open. 2020;4(3):485-497doi: 10.1007/s41669-019-00186-7.
Oyagüez, I., Suárez, C., López-Sendón, J. L., González-Juanatey, J. R., de Andrés-Nogales, F., Suárez, J., Polanco, C., & Soto, J. (2020). Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention. PharmacoEconomics - open, 4(3), 485-497. https://doi.org/10.1007/s41669-019-00186-7
Oyagüez, Itziar, et al. "Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention." PharmacoEconomics - open vol. 4,3 (2020): 485-497. doi: https://doi.org/10.1007/s41669-019-00186-7
Oyagüez I, Suárez C, López-Sendón JL, González-Juanatey JR, de Andrés-Nogales F, Suárez J, Polanco C, Soto J. Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention. Pharmacoecon Open. 2020 Sep;4(3):485-497. doi: 10.1007/s41669-019-00186-7. PMID: 31673882; PMCID: PMC7426339.
Copy Download .nbib Format: NLM
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).

European heart journal. Quality of care & clinical outcomes

Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Grégoire JC, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Ostadal P, Lopez-Sendon J, Gamra H, Kiwan GS, Dubé MP, Provencher M, Orfanos A, Blondeau L, Kouz S, L'Allier PL, Ibrahim R, Bouabdallaoui N, Mitchell D, Guertin MC, Lelorier J.
PMID: 32407460
Eur Heart J Qual Care Clin Outcomes. 2021 Sep 16;7(5):486-495. doi: 10.1093/ehjqcco/qcaa045.

AIMS: In the randomized, placebo-controlled Colchicine Cardiovascular Outcomes Trial (COLCOT) of 4745 patients enrolled within 30 days after myocardial infarction (MI), low-dose colchicine (0.5 mg once daily) reduced the incidence of the primary composite endpoint of cardiovascular death, resuscitated...

Cite
Samuel M, Tardif JC, Khairy P, et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes. 2021;7(5):486-495doi: 10.1093/ehjqcco/qcaa045.
Samuel, M., Tardif, J. C., Khairy, P., Roubille, F., Waters, D. D., Grégoire, J. C., Pinto, F. J., Maggioni, A. P., Diaz, R., Berry, C., Koenig, W., Ostadal, P., Lopez-Sendon, J., Gamra, H., Kiwan, G. S., Dubé, M. P., Provencher, M., Orfanos, A., Blondeau, L., Kouz, S., L'Allier, P. L., Ibrahim, R., Bouabdallaoui, N., Mitchell, D., Guertin, M. C., & Lelorier, J. (2021). Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). European heart journal. Quality of care & clinical outcomes, 7(5), 486-495. https://doi.org/10.1093/ehjqcco/qcaa045
Samuel, Michelle, et al. "Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)." European heart journal. Quality of care & clinical outcomes vol. 7,5 (2021): 486-495. doi: https://doi.org/10.1093/ehjqcco/qcaa045
Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Grégoire JC, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Ostadal P, Lopez-Sendon J, Gamra H, Kiwan GS, Dubé MP, Provencher M, Orfanos A, Blondeau L, Kouz S, L'Allier PL, Ibrahim R, Bouabdallaoui N, Mitchell D, Guertin MC, Lelorier J. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes. 2021 Sep 16;7(5):486-495. doi: 10.1093/ehjqcco/qcaa045. PMID: 32407460; PMCID: PMC8445085.
Copy Download .nbib Format: NLM
ISCHEMIA Trial: Key Questions and Answers.

European cardiology

Lopez-Sendon J, Moreno R, Tamargo J.
PMID: 34603514
Eur Cardiol. 2021 Sep 14;16:e34. doi: 10.15420/ecr.2021.16. eCollection 2021 Feb.

A healthy lifestyle, myocardial revascularisation and medical therapy constitute the three pillars for the treatment of ischaemic heart disease. Lifestyle and optimal medical therapy should be used in all cases. However, the selection of cases for revascularisation among stable...

Cite
Lopez-Sendon J, Moreno R, Tamargo J. ISCHEMIA Trial: Key Questions and Answers. Eur Cardiol. 2021;16:e34doi: 10.15420/ecr.2021.16.
Lopez-Sendon, J., Moreno, R., & Tamargo, J. (2021). ISCHEMIA Trial: Key Questions and Answers. European cardiology, 16e34. https://doi.org/10.15420/ecr.2021.16
Lopez-Sendon, Jose, et al. "ISCHEMIA Trial: Key Questions and Answers." European cardiology vol. 16 (2021): e34. doi: https://doi.org/10.15420/ecr.2021.16
Lopez-Sendon J, Moreno R, Tamargo J. ISCHEMIA Trial: Key Questions and Answers. Eur Cardiol. 2021 Sep 14;16:e34. doi: 10.15420/ecr.2021.16. eCollection 2021 Feb. PMID: 34603514; PMCID: PMC8477173.
Copy Download .nbib Format: NLM
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial.

European heart journal. Cardiovascular pharmacotherapy

De Caterina R, Patti G, Westerbergh J, Horowitz J, Ezekowitz JA, Lewis BS, Lopes RD, McMurray JJV, Atar D, Bahit MC, Keltai M, López-Sendón JL, Ruzyllo W, Granger CB, Alexander JH, Wallentin L.
PMID: 33367487
Eur Heart J Cardiovasc Pharmacother. 2020 Dec 28; doi: 10.1093/ehjcvp/pvaa140. Epub 2020 Dec 28.

AIMS: Whether diabetes without insulin therapy is an independent cardiovascular (CV) risk factor in atrial fibrillation (AF) has recently been questioned. We investigated the prognostic relevance of diabetes with or without insulin treatment in patients in the ARISTOTLE trial.METHODS...

Cite
De Caterina R, Patti G, Westerbergh J, et al. Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2020;doi: 10.1093/ehjcvp/pvaa140.
De Caterina, R., Patti, G., Westerbergh, J., Horowitz, J., Ezekowitz, J. A., Lewis, B. S., Lopes, R. D., McMurray, J. J. V., Atar, D., Bahit, M. C., Keltai, M., López-Sendón, J. L., Ruzyllo, W., Granger, C. B., Alexander, J. H., & Wallentin, L. (2020). Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European heart journal. Cardiovascular pharmacotherapy, . https://doi.org/10.1093/ehjcvp/pvaa140
De Caterina, Raffaele, et al. "Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial." European heart journal. Cardiovascular pharmacotherapy vol. (2020). doi: https://doi.org/10.1093/ehjcvp/pvaa140
De Caterina R, Patti G, Westerbergh J, Horowitz J, Ezekowitz JA, Lewis BS, Lopes RD, McMurray JJV, Atar D, Bahit MC, Keltai M, López-Sendón JL, Ruzyllo W, Granger CB, Alexander JH, Wallentin L. Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2020 Dec 28; doi: 10.1093/ehjcvp/pvaa140. Epub 2020 Dec 28. PMID: 33367487.
Copy Download .nbib Format: NLM
Organized atrial tachycardias after atrial fibrillation ablation.

Cardiology research and practice

Castrejón-Castrejón S, Ortega M, Pérez-Silva A, Doiny D, Estrada A, Filgueiras D, López-Sendón JL, Merino JL.
PMID: 21941669
Cardiol Res Pract. 2011;2011:957538. doi: 10.4061/2011/957538. Epub 2011 Sep 19.

The efficacy of catheter-based ablation techniques to treat atrial fibrillation is limited not only by recurrences of this arrhythmia but also, and not less importantly, by new-onset organized atrial tachycardias. The incidence of such tachycardias depends on the type...

Cite
Castrejón-Castrejón S, Ortega M, Pérez-Silva A, et al. Organized atrial tachycardias after atrial fibrillation ablation. Cardiol Res Pract. 2011;2011:957538doi: 10.4061/2011/957538.
Castrejón-Castrejón, S., Ortega, M., Pérez-Silva, A., Doiny, D., Estrada, A., Filgueiras, D., López-Sendón, J. L., & Merino, J. L. (2011). Organized atrial tachycardias after atrial fibrillation ablation. Cardiology research and practice, 2011957538. https://doi.org/10.4061/2011/957538
Castrejón-Castrejón, Sergio, et al. "Organized atrial tachycardias after atrial fibrillation ablation." Cardiology research and practice vol. 2011 (2011): 957538. doi: https://doi.org/10.4061/2011/957538
Castrejón-Castrejón S, Ortega M, Pérez-Silva A, Doiny D, Estrada A, Filgueiras D, López-Sendón JL, Merino JL. Organized atrial tachycardias after atrial fibrillation ablation. Cardiol Res Pract. 2011;2011:957538. doi: 10.4061/2011/957538. Epub 2011 Sep 19. PMID: 21941669; PMCID: PMC3175708.
Copy Download .nbib Format: NLM
Innate Immune Receptors, Key Actors in Cardiovascular Diseases.

JACC. Basic to translational science

Jaén RI, Val-Blasco A, Prieto P, Gil-Fernández M, Smani T, López-Sendón JL, Delgado C, Boscá L, Fernández-Velasco M.
PMID: 32760860
JACC Basic Transl Sci. 2020 Jul 27;5(7):735-749. doi: 10.1016/j.jacbts.2020.03.015. eCollection 2020 Jul.

Cardiovascular diseases (CVDs) are the leading cause of death in the industrialized world. Most CVDs are associated with increased inflammation that arises mainly from innate immune system activation related to cardiac damage. Sustained activation of the innate immune system...

Cite
Jaén RI, Val-Blasco A, Prieto P, et al. Innate Immune Receptors, Key Actors in Cardiovascular Diseases. JACC Basic Transl Sci. 2020;5(7):735-749doi: 10.1016/j.jacbts.2020.03.015.
Jaén, R. I., Val-Blasco, A., Prieto, P., Gil-Fernández, M., Smani, T., López-Sendón, J. L., Delgado, C., Boscá, L., & Fernández-Velasco, M. (2020). Innate Immune Receptors, Key Actors in Cardiovascular Diseases. JACC. Basic to translational science, 5(7), 735-749. https://doi.org/10.1016/j.jacbts.2020.03.015
Jaén, Rafael I, et al. "Innate Immune Receptors, Key Actors in Cardiovascular Diseases." JACC. Basic to translational science vol. 5,7 (2020): 735-749. doi: https://doi.org/10.1016/j.jacbts.2020.03.015
Jaén RI, Val-Blasco A, Prieto P, Gil-Fernández M, Smani T, López-Sendón JL, Delgado C, Boscá L, Fernández-Velasco M. Innate Immune Receptors, Key Actors in Cardiovascular Diseases. JACC Basic Transl Sci. 2020 Jul 27;5(7):735-749. doi: 10.1016/j.jacbts.2020.03.015. eCollection 2020 Jul. PMID: 32760860; PMCID: PMC7393405.
Copy Download .nbib Format: NLM
Atrial arrhythmias in obstructive sleep apnea: underlying mechanisms and implications in the clinical setting.

Pulmonary medicine

Filgueiras-Rama D, Arias MA, Iniesta A, Armada E, Merino JL, Peinado R, López-Sendón JL.
PMID: 23691306
Pulm Med. 2013;2013:426758. doi: 10.1155/2013/426758. Epub 2013 Apr 03.

Obstructive sleep apnea (OSA) is a common disorder characterized by repetitive interruption of ventilation during sleep caused by recurrent upper airway collapse, which leads to intermittent hypoxia. The disorder is commonly undiagnosed despite its relationship with substantial cardiovascular morbidity...

Cite
Filgueiras-Rama D, Arias MA, Iniesta A, et al. Atrial arrhythmias in obstructive sleep apnea: underlying mechanisms and implications in the clinical setting. Pulm Med. 2013;2013:426758doi: 10.1155/2013/426758.
Filgueiras-Rama, D., Arias, M. A., Iniesta, A., Armada, E., Merino, J. L., Peinado, R., & López-Sendón, J. L. (2013). Atrial arrhythmias in obstructive sleep apnea: underlying mechanisms and implications in the clinical setting. Pulmonary medicine, 2013426758. https://doi.org/10.1155/2013/426758
Filgueiras-Rama, David, et al. "Atrial arrhythmias in obstructive sleep apnea: underlying mechanisms and implications in the clinical setting." Pulmonary medicine vol. 2013 (2013): 426758. doi: https://doi.org/10.1155/2013/426758
Filgueiras-Rama D, Arias MA, Iniesta A, Armada E, Merino JL, Peinado R, López-Sendón JL. Atrial arrhythmias in obstructive sleep apnea: underlying mechanisms and implications in the clinical setting. Pulm Med. 2013;2013:426758. doi: 10.1155/2013/426758. Epub 2013 Apr 03. PMID: 23691306; PMCID: PMC3649713.
Copy Download .nbib Format: NLM
[Silent ischemia. To treat or not to treat?].

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology

López-Sendón J, Ramos F, Gonzalez Maqueda I.
PMID: 2189463
Rev Port Cardiol. 1990 Feb;9(2):161-6.

Silent myocardial ischaemia can be defined as the presence of transient ischaemic alterations in absence of angina. Those include metabolic, functional, electrocardiographic and anatomic abnormalities without typical chest pain. Its incidence, prognostic significance, possible identification in clinical practice as...

Cite
López-Sendón J, Ramos F, Gonzalez Maqueda I. Isquemia silente. Tratar o no tratar? [Silent ischemia. To treat or not to treat?]. Rev Port Cardiol. 1990;9(2):161-6
López-Sendón, J., Ramos, F., & Gonzalez Maqueda, I. (1990). Isquemia silente. Tratar o no tratar? [Silent ischemia. To treat or not to treat?]. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 9(2), 161-6.
López-Sendón, J, et al. "Isquemia silente. Tratar o no tratar?" [Silent ischemia. To treat or not to treat?]. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology vol. 9,2 (1990): 161-6.
López-Sendón J, Ramos F, Gonzalez Maqueda I. Isquemia silente. Tratar o no tratar? [Silent ischemia. To treat or not to treat?]. Rev Port Cardiol. 1990 Feb;9(2):161-6. Spanish. PMID: 2189463.
Copy Download .nbib Format: NLM
Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study.

European journal of preventive cardiology

Gaudet D, López-Sendón JL, Averna M, Bigot G, Banach M, Letierce A, Loy M, Samuel R, Manvelian G, Batsu I, Henry P.
PMID: 33624041
Eur J Prev Cardiol. 2020 Nov 22; doi: 10.1093/eurjpc/zwaa097. Epub 2020 Nov 22.

AIMS: To obtain safety and efficacy data of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in a real-life setting in high cardiovascular (CV) risk patients with heterozygous familial hypercholesterolaemia (HeFH) or very-high low-density lipoprotein cholesterol (LDL-C) levels despite...

Cite
Gaudet D, López-Sendón JL, Averna M, et al. Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. Eur J Prev Cardiol. 2020;doi: 10.1093/eurjpc/zwaa097.
Gaudet, D., López-Sendón, J. L., Averna, M., Bigot, G., Banach, M., Letierce, A., Loy, M., Samuel, R., Manvelian, G., Batsu, I., & Henry, P. (2020). Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. European journal of preventive cardiology, . https://doi.org/10.1093/eurjpc/zwaa097
Gaudet, Daniel, et al. "Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study." European journal of preventive cardiology vol. (2020). doi: https://doi.org/10.1093/eurjpc/zwaa097
Gaudet D, López-Sendón JL, Averna M, Bigot G, Banach M, Letierce A, Loy M, Samuel R, Manvelian G, Batsu I, Henry P. Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. Eur J Prev Cardiol. 2020 Nov 22; doi: 10.1093/eurjpc/zwaa097. Epub 2020 Nov 22. PMID: 33624041.
Copy Download .nbib Format: NLM
Ranolazine: a better understanding of pathophysiology and patient profile to guide treatment of chronic stable angina.

Future cardiology

Tamargo J, Lopez-Sendon J.
PMID: 34841884
Future Cardiol. 2021 Nov 29; doi: 10.2217/fca-2021-0058. Epub 2021 Nov 29.

Chronic stable angina pectoris, the most prevalent symptomatic manifestation of coronary artery disease, greatly impairs quality of life and is associated with an increased risk for adverse cardiovascular outcomes. Better understanding of the pathophysiologic mechanisms of myocardial ischemia permitted...

Cite
Tamargo J, Lopez-Sendon J. Ranolazine: a better understanding of pathophysiology and patient profile to guide treatment of chronic stable angina. Future Cardiol. 2021;doi: 10.2217/fca-2021-0058.
Tamargo, J., & Lopez-Sendon, J. (2021). Ranolazine: a better understanding of pathophysiology and patient profile to guide treatment of chronic stable angina. Future cardiology, . https://doi.org/10.2217/fca-2021-0058
Tamargo, Juan, and Lopez-Sendon, Jose. "Ranolazine: a better understanding of pathophysiology and patient profile to guide treatment of chronic stable angina." Future cardiology vol. (2021). doi: https://doi.org/10.2217/fca-2021-0058
Tamargo J, Lopez-Sendon J. Ranolazine: a better understanding of pathophysiology and patient profile to guide treatment of chronic stable angina. Future Cardiol. 2021 Nov 29; doi: 10.2217/fca-2021-0058. Epub 2021 Nov 29. PMID: 34841884.
Copy Download .nbib Format: NLM
Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice.

Neurologia (Barcelona, Spain)

Pérez-Torre P, López-Sendón JL, Mañanes Barral V, Parees I, Fanjul-Arbós S, Monreal E, Alonso-Canovas A, Martínez Castrillo JC.
PMID: 34518027
Neurologia (Engl Ed). 2021 Sep 10; doi: 10.1016/j.nrl.2021.08.004. Epub 2021 Sep 10.

BACKGROUND AND PURPOSE: The aim of this study was to assess the possible pharmacological interactions between safinamide and antidepressants, and in particular the appearance of serotonin syndrome with data from real life.METHODS: We conducted a retrospective observational study of...

Cite
Pérez-Torre P, López-Sendón JL, Mañanes Barral V, et al. Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice. Neurologia (Engl Ed). 2021;doi: 10.1016/j.nrl.2021.08.004.
Pérez-Torre, P., López-Sendón, J. L., Mañanes Barral, V., Parees, I., Fanjul-Arbós, S., Monreal, E., Alonso-Canovas, A., & Martínez Castrillo, J. C. (2021). Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice. Neurologia (Barcelona, Spain), . https://doi.org/10.1016/j.nrl.2021.08.004
Pérez-Torre, P, et al. "Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice." Neurologia (Barcelona, Spain) vol. (2021). doi: https://doi.org/10.1016/j.nrl.2021.08.004
Pérez-Torre P, López-Sendón JL, Mañanes Barral V, Parees I, Fanjul-Arbós S, Monreal E, Alonso-Canovas A, Martínez Castrillo JC. Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice. Neurologia (Engl Ed). 2021 Sep 10; doi: 10.1016/j.nrl.2021.08.004. Epub 2021 Sep 10. Spanish. PMID: 34518027.
Copy Download .nbib Format: NLM
Clinical and prognostic implications of atrial fibrillation in patients undergoing transcatheter aortic valve implantation.

World journal of cardiology

Salinas P, Moreno R, Calvo L, Jiménez-Valero S, Galeote G, Sánchez-Recalde A, López-Fernández T, Garcia-Blas S, Iglesias D, Riera L, Moreno-Gómez I, Mesa JM, Plaza I, Ayala R, Gonzalez R, López-Sendón JL.
PMID: 22279599
World J Cardiol. 2012 Jan 26;4(1):8-14. doi: 10.4330/wjc.v4.i1.8.

AIM: To study a cohort of consecutive patients undergoing transcatheter aortic valve implantation (TAVI) and compare the outcomes of atrial fibrillation (AF) patients vs patients in sinus rhythm (SR).METHODS: All consecutive patients undergoing TAVI in our hospital were included....

Cite
Salinas P, Moreno R, Calvo L, et al. Clinical and prognostic implications of atrial fibrillation in patients undergoing transcatheter aortic valve implantation. World J Cardiol. 2012;4(1):8-14doi: 10.4330/wjc.v4.i1.8.
Salinas, P., Moreno, R., Calvo, L., Jiménez-Valero, S., Galeote, G., Sánchez-Recalde, A., López-Fernández, T., Garcia-Blas, S., Iglesias, D., Riera, L., Moreno-Gómez, I., Mesa, J. M., Plaza, I., Ayala, R., Gonzalez, R., & López-Sendón, J. L. (2012). Clinical and prognostic implications of atrial fibrillation in patients undergoing transcatheter aortic valve implantation. World journal of cardiology, 4(1), 8-14. https://doi.org/10.4330/wjc.v4.i1.8
Salinas, Pablo, et al. "Clinical and prognostic implications of atrial fibrillation in patients undergoing transcatheter aortic valve implantation." World journal of cardiology vol. 4,1 (2012): 8-14. doi: https://doi.org/10.4330/wjc.v4.i1.8
Salinas P, Moreno R, Calvo L, Jiménez-Valero S, Galeote G, Sánchez-Recalde A, López-Fernández T, Garcia-Blas S, Iglesias D, Riera L, Moreno-Gómez I, Mesa JM, Plaza I, Ayala R, Gonzalez R, López-Sendón JL. Clinical and prognostic implications of atrial fibrillation in patients undergoing transcatheter aortic valve implantation. World J Cardiol. 2012 Jan 26;4(1):8-14. doi: 10.4330/wjc.v4.i1.8. PMID: 22279599; PMCID: PMC3262396.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 37 entries